Abstract
Platelet-associated antibodies (PAA) from schizophrenic patients and healthy individuals were determined by conventional enzyme immunoassay. The platelets of the schizophrenic patients were found to carry notably higher levels of PAA than were those of the healthy controls. PAA from the schizophrenics inhibited specifically the uptake of dopamine (DA) by platelets. The DA uptake by normal platelets could be reduced to a level similar to that observed in platelets of schizophrenics upon binding of PAA from schizophrenics. Serotonin uptake was virtually unaffected by these antibodies. The Vmax value of dopamine uptake by platelets of schizophrenics was similar to that for normal platelets treated with PAA of schizophrenics, as well as that for normal untreated platelets. However, the Km values of the uptake were higher in the platelets from schizophrenics and normals treated with PAA from schizophrenics than in the untreated platelets of normals. PAA from schizophrenics were found to bind to rat brain P2m membranes and to interfere with the binding of the dopamine receptor ligands [3H]-dopamine and [3H]-spiperone. These results suggest that blood platelets may function as a peripheral epitope for the formation of PAA, which, when reaching the brain, may react with the dopamine receptor and elicit mental disorder.
Article PDF
Similar content being viewed by others
References
Abramsky, O., & Litvin, Y. (1978). Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson’s disease and schizophrenia. Perspectives in Biology & Medicine, 22, 104–114.
Ader, R., Cohen, N., & Felten, J. J. (1987). Brain, behavior and immunity. Brain, Behavior & Immunity, 1, 1–6.
American Psychiatric Association (1987). Diagnostic and statistical manual of mental disorders-III. Washington, DC: Author.
Amkraut, A., Solomon, G. F., Allansmith, M., McClellan, G., & Rappaport, M. (1973). Immunoglobulins and improvement in acute schizophrenic reactions. Archives of General Psychiatry, 28, 673–677.
Barbeau, A., & Campanella, G. (1975). Uptake and efflux of 14C-dopamine in platelets: Evidence for generalized defect in Parkinson’s disease. Neurologica, 25, 1–9.
Baron, M., Stern, M., Anavi, R., & Witz, I. P. (1977). Tissue-binding factor in schizophrenic sera: A clinical and genetic study. Biological Psychiatry, 12, 199–207.
Boullin, D. J., Orr, M. W., & Peters, J. R. (1978). The platelet as a model for investigating the clinical efficacy of centrally acting drugs in schizophrenics. In G. Gaetano & S. Garatini (Ed.), Platelets: A multidisciplinary approach (pp. 389–410). New York: Raven.
Carlsson, A. (1978). Antipsychiotic drugs, neurotransmitters and schizophrenia. American Journal of Psychiatry, 135, 164–173.
Carlton, P. L., & Manowitz, P. (1984). Dopamine and schizophrenia: An analysis of the theory. Neuroscience & Biobehavioral Reviews, 8, 137–151.
Carnegie, P. R., & MacKay, I. R. (1975). Vulnerability of cell-surface receptors to autoimmune reactions. Lancet, 2, 684–686.
Cawley, L. P., James, V. L., Minard, B. J., & Bryant, S. A. (1984). Antibodies to Purkinje cells and peripheral nerve in opoclonia. Lancet, 21, 509–510.
Cohen, I. R. (1992). The cognitive principle challenges clonal selection. Immunology Today, 13, 441–444.
Crow, T. J. (1980). Molecular pathology of schizophrenia: More than one disease process? British Medical Journal, 280, 66–68.
Dean, B., & Copolov, D. L. (1989). Dopamine uptake by platelets is selective, temperature dependent and not influenced by the dopamine-D1 or dopamine-D2 receptor, Life Sciences, 45, 401–411.
DeLisi, L. E., & Crow, T. J. (1986). Is schizophrenia a viral or immunological disorder? Psychiatric Clinics of North America, 9, 115–132.
DeLisi, L. E., King, A. K., & Targum, S. (1984). Serum immunoglobulin concentration in patients admitted to an acute psychiatric inpatient service. British Journal of Psychiatry, 145, 661–664.
DeLisi, L. E., Weber, R. J., & Pert, C. B. (1985). Are there antibodies against brain in sera from schizophrenic patients? Biological Psychiatry, 20, 94–119.
DeLisi, L. E., Weinberger, D. R., Neckars, L. M., Potion, S., Shiling, D. J., & Wyatt, R. J. (1981). Quantitative determination of immunoglobulins in CSF and plasma of chronic schizophrenic patients. British Journal of Psychiatry, 139, 513–518.
Fudenberg, H. H., Whitten, H. D., Merler, E., & Farmati, O. (1983). Is schizophrenia an autoimmunologic receptor disorder? Medical Hypotheses, 12, 85–93.
Ganguli, R., Rabin, B. S., Kelly, R. H., Lyte, M., & Ragu, U. (1987). Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Annals of the New York Academy of Sciences, 496, 676–690.
Gordon, J. L., & Overman, H. J. (1978). Hydroxytryptamine and dopamine transport by rat and human blood platelets. British Journal of Pharmacology, 62, 219–226.
Greenlee, G. E., & Brashear, H. R. (1983). Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovian carcinoma. Annals of Neurology, 14, 609–613.
Heath, R. G., & Krupp, I. M. (1967). Schizophrenia as an immunologic disorder: 1. Demonstration of antibrain globulins by fluorescent antibody techniques. Archives of General Psychiatry, 16, 1–9.
Hofstein, R., Segal, M., & Samuel, D. (1980). Antibodies to synaptosomal membranes of rat hippocampus and caudate nucleus: Immunological and behavioral characteristics. Experimental Neurology, 70, 307–320.
Hornykiewicz, O. (1963). Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamine in der substantia Nigra des normalen und parkinsonkranken Menschen. Klinische Wochenschrift, 75, 309–312.
Husby, G., Li, L., Davis, L. E., Wedege, E., Kokmen, E., & Williams-Jr., R. C. (1977). Antibodies to human caudate nucleus in Huntington’s chorea. Journal of Clinical Investigation, 59, 922–932.
Jankovic, B. D. (1984). From immunoneurology to immunopsychiatry: Neuromodulating activity of antibrain antibodies. International Review of Neurobiology, 26, 249–314.
Jankovic, B. D. (1985). Neural tissue hypersensitivity. Journal of Immunology, 135, 853–857.
Karpiak, S. I., Serokosz, M., & Rappaport, M. (1976). Effects of antisera to S-100 protein and to synaptic membrane fraction on maze performance and EEC Brain Research, 102, 313–321.
Kelton, J. G., & Dénomme, G. (1982). The quantitation of platelet-associated IgG on cohorts of platelets separated from healthy individuals by buoyant density centrifugation. Blood, 60, 136–139.
Kelton, J. G., Murphy, W. G., Lucarelli, A., Garvey-Williams, J., Santos, A., Meyer, R., & Powers, P. (1989). A prospective comparison of four techniques for measuring platelet associated IgG. British Journal of Haematology, 71, 97–105.
King, M., McDermott, P., & Schreiber, A. D. (1990). Characterization of the Fcγ receptor on human platelets. Cellular Immunology, 128, 462–479.
Kirchbach, A., Fisher, V., Eike, G., & Kornhuber, H. H. (1987). Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients. Journal of Neural Transmission, 70, 175–179.
Klein, D. F., Gittelman, R., Quitkin, F., & Rifkin, F. (1980). Diagnosis and drug treatment of psychiatric disorders: Adults and children. Baltimore: Williams & Wilkins.
Knight, J. G. (1982). Dopamine receptor stimulating antibodies: A possible cause of schizophrenia. Lancet, 13, 1073–1076.
Knight, J. G. (1984). Is schizophrenia an autoimmune disease? A review. Methods & Findings in Experimental & Clinical Pharmacology, 6, 395–411.
Kunicki, T. J., Kristopeit, S. M., & Aster, R. H. (1982). Direct quantitation of platelet-associated IgG by electroimmunoassay. Blood, 60, 54–58.
Lefvert, A. K., & Pirskanen, R. (1977). Acetylcholine-receptor antibodies in cerebrospinal fluid of patients with myasthenia gravis. Lancet, 13, 351–352.
Leporrier, M., Dighiero, G., Auzemery, M., & Binet, J. L. (1979). Detection and quantification of platelet-bound antibodies with immunoperoxidase. British Journal of Haematology, 42, 605–611.
Liddle, P. F. (1987). The symptoms of chronic schizophrenia: A re-examination of the positive-negative dichotomy. British Journal of Psychiatry, 151, 145–151.
Lingjaerde, O. (1977). Platelet uptake and storage of serotonin. In E. W. Essan (Ed.), Serotonin in health and disease (pp. 129–199). New York: Spectrum.
Lingjaerde, O., & Kildemo, O. (1981). Dopamine uptake in platelets: Two different low affinity saturable mechanisms. Agents & Actions, 11, 410–416.
Luiken, G. A., McMillan, R., Lightsey, A. L., Gordon, P., Zevely, S., Shulman, I., Gribble, T. J., & Longmine, R. L. (1972). Platelet associated IgG in immune thrombocytopenia purpura. Blood, 50, 317–325.
Malmgren, R. (1984). Platelets andbiogenic amines: 1. Platelets are poor investigative models for dopamine re-uptake. Psychopharmacology, 84, 480–485.
Markus, A. J., Salier, L. B., Ullman, H. L., Islama, T., Broekman, M. J., Falck, J. R., Fischer, S., & von-Schacky, C. (1988). Platelet-neutrophil interactions. Journal of Biological Chemistry, 263, 2223–2229.
Meltzer, H., & Stahl, S. M. (1976). The dopamine hypothesis of schizophrenia. Schizophrenia Bulletin, 2, 19–76.
Morgan, J. G., Wolfe, L. S., Mandel, P., & Gombes, G. (1971). Isolation of plasma membranes from rat brain. Biochimica Biophysica Acta, 241, 737–751.
Morse, B. S., Giulani, D., & Nussbaum, M. (1981). Quantitation of platelet-associated IgG by radial immunodifrusion. Blood, 57, 809–811.
Mueller-Eckhardt, C., Kayser, W., & Mersch-Baumert, M. M. (1980). Clinical significance of platelet-asociated IgG: A study on 298 patients with various disorders. British Journal of Haematology, 46, 123–131.
Omenn, G. S., & Smith, L. T. (1978). A common uptake system for serotonin and dopamine in human platelets. Journal of Clinical Investigation, 58, 235–240.
Pandey, R. S., Gupta, A. K., & Chaturvedi, V. C. (1981). Autoimmune model of schizophrenia with special reference to anti-brain antibodies. Biological Psychiatry, 16, 1123–1136.
Pfueller, S. L., & David, R. (1986). Liveration of surface and internal platelet associated IgG (PA-IgG) during platelet activation. British Journal of Haematology, 63, 785–794.
Pfueller, S. L., Weber, S., & Luescher, E. F. (1977). Studies of the mechanism of the human platelet reaction induced by immunologic stimuli. Journal of Immunology, 118, 514–524.
Pletcher, A., Affolter, H., Cesura, M., Erne, E., & Mueller, K. (1984). Blood platelets as models for neurons: Similarities of the 5-hydroxytryptamine systems. In H. G. Schlossberger, W. Kochen, B. Linzen, & H. Steinhart (Eds.), Progress in tryptophan and serotonin research (pp. 231–239). Berlin: De Gruyter.
Rotman, A., Munitz, H., Modai, J., Tjano, S., & Wljsenbeck, H. (1980). Comparative uptake study of serotonin, dopamine and norepinephrine by platelets of acute schizophrenic patients. Psychological Review, 3, 239–246.
Seeman, P. (1987). Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1, 133–152.
Shinitzky, M., Deckman, M., Kessler, A., Sirota, P., Rabbs, A., & Elizur, A. (1991). Platelet autoantibodies in dementia and schizophrenia—possible implication for mental disorders. Annals of the New York Academy of Sciences, 621, 205–217.
Sneddon, M. (1973). Blood platelets as a model for monoamine containing neurons. In G. A. Kerkut & J. W. Phillips (Eds.), Progress in neurobiology (pp. 151–192). New York: Pergamon.
Solomon, G. F. (1987). Psychoneuroimmunology: Interactions between central nervous system and immune systems. Journal of Neuroscience Research, 18, 1–9.
Solomon, H. M., Spirt, N. M., & Abrams, W. B. (1970). The accumulation and metabolism of dopamine by the human platelet. Clinical Pharmacology & Therapeutics, 11, 838–845.
Teplizki, H. A., Sela, B., & Shoenfeld, Y. (1992). Autoantibodies to brain and polynucleotides in patients with schizophrenia: A puzzle. Immunologic Research, 11, 66–73.
Trotter, G. L., Hendin, B. A., & Osterland, K. (1976). Cerebellar degeneration with Hodgkin disease. Archives of Neurology, 33, 660–661.
Tsuang, M. T., Lyons, M. J., & Faraone, S. V. (1990). Heterogeneity of schizophrenia: Conceptual models and analytic strategies. British Journal of Psychiatry, 156, 17–26.
Tucker, D. F., Begent, R. H. J., & Hogg, N. M. (1978). Characterization of immune complexes in serum by adsorption staphylococcal protein. American Journal of Immunology, 121, 1644–1659.
Whittingham, S., Mackay, I. R., Jones, I. H., & Davis, B. (1968). Absence of brain antibodies in patients with schizophrenia. British Medical Journal, 1, 347–348.
Wilchek, M., & Miron, T. (1982). Immobilization of enzymes and affinity ligands onto agarose via stable and uncharged carbamate linkages. Biochemistry International, 4, 629–635.
Wong, D. F., Wagner, H. N., Tune, L. E., Dannals, R. F., Pearlson, G. D., Links, J. M., Tamminga, C. A., Bronssolle, E. P., Ravert, H. T., Wilson, A. A., Toung, T., Malat, J., Williams, J. A., O’Tuama, L. A., Snyder, S. H., Kuhar, M. J., & Gjedde, A. (1986). Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science, 234, 1558–1563.
Author information
Authors and Affiliations
Additional information
This research was supported by a grant from the MINERVA Foundation, Munich, Germany.
Rights and permissions
About this article
Cite this article
Kessler, A., Shinitzky, M. Platelets from schizophrenic patients bear autoimmune antibodies that inhibit dopamine uptake. Psychobiology 21, 299–306 (1993). https://doi.org/10.3758/BF03327149
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3758/BF03327149